Genentech is strengthening its oncology pipeline by acquiring Regor Pharmaceuticals’ portfolio of breast cancer ...

This growth is driven by a rise in cancer diagnoses, promising results from early-phase clinical trials of CDK inhibitors such as Samuraciclib and Q901, and the growing number of these inhibitors ...

The co-crystallization of indigoids with CDK2 reveals many details about the atomic interactions of the inhibitors with the CDK, and will be helpful in the synthesis of new, and hopefully potent ...

In an interview with Targeted Oncology, Erika Hamilton, MD, discussed emerging endocrine therapies that are advancing breast ...

In a first renal outcome trial of its kind, the SGLT2 inhibitor showed favorable outcomes in the most advanced stages of CKD.

Title: CID-078, a First-in-Class Oral Macrocycle Cyclin A/B RxL Inhibitor, Demonstrates Anti ... in vivo models with dysregulated cell cycle (CDK-RB-E2F) function. Notably, tumor regressions ...

triple negative breast cancer and ER+ HER-2- breast cancer following CDK 4/6-inhibitor therapy. “We are thrilled that the IND for CID-078 was cleared at the end of the 30-day regulatory review ...

Among the many impactful sessions, a symposium titled ‘Incorporating Novel Treatment Insights for Estrogen Receptor-Positive (ER+) Early Breast Cancer Patients’ garnered particular attention.

Cambridge, Massachusetts-based biotech Regor Therapeutics Group has agreed to sell its portfolio of CDK inhibitors for the treatment of breast cancer to Roche's Genentech for an upfront cash ...